ERBB2 and cancer: Finally, once T-DXd is internalized and processed by the target cells, it has a unique ability to enter the surrounding cells and induce a bystander killing effect to the off-target cancer cells, maximizing its therapeutic efficacy even in tumors with heterogeneous expressions of HER2 (12, 14).